tiprankstipranks
SK Biopharmaceuticals Co., Ltd. (KR:326030)
:326030
South Korea Market
326030
SK Biopharmaceuticals Co., Ltd.
RESEARCH TOOLSreports

SK Biopharmaceuticals Co., Ltd. (326030) Financial Statements

― Followers

SK Biopharmaceuticals Co., Ltd. Financial Overview

SK Biopharmaceuticals Co., Ltd.'s market cap is currently ₩6.53T. The company's EPS TTM is $4945.34; its P/E ratio is 16.06; SK Biopharmaceuticals Co., Ltd. is scheduled to report earnings on August 5, 2026, and the estimated EPS forecast is $594.78. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue₩ 706.74B₩ 547.60B₩ 354.89B₩ 246.18B₩ 418.64B
Gross Profit₩ 651.67B₩ 504.50B₩ 320.81B₩ 208.41B₩ 396.31B
Operating Income₩ 203.94B₩ 96.34B₩ -20.63B₩ -131.08B₩ 94.96B
EBITDA₩ 220.89B₩ 100.71B₩ -8.73B₩ -125.77B₩ 167.68B
Net Income₩ 266.95B₩ 240.74B₩ -32.88B₩ -139.43B₩ 64.85B
Balance Sheet
Cash & Short-Term Investments₩ 309.48B₩ 324.49B₩ 241.12B₩ 305.45B₩ 334.34B
Total Assets₩ 1.20T₩ 1.04T₩ 723.17B₩ 664.24B₩ 643.65B
Total Debt₩ 48.92B₩ 184.48B₩ 178.05B₩ 155.90B₩ 15.74B
Net Debt₩ -258.85B₩ -138.32B₩ -61.65B₩ 51.84B₩ -210.18B
Total Liabilities₩ 372.04B₩ 462.83B₩ 402.22B₩ 347.68B₩ 199.46B
Stockholders' Equity₩ 813.04B₩ 546.27B₩ 283.69B₩ 316.56B₩ 444.19B
Cash Flow
Free Cash Flow₩ 173.64B₩ 81.48B₩ -97.45B₩ -165.88B₩ -98.86B
Operating Cash Flow₩ 180.53B₩ 94.90B₩ -94.20B₩ -159.92B₩ -92.87B
Investing Cash Flow₩ -35.42B₩ -10.94B₩ 225.27B₩ -95.71B₩ 258.97B
Financing Cash Flow₩ -156.68B₩ -4.50B₩ 6.62B₩ 134.91B₩ -4.65B
Currency in KRW

SK Biopharmaceuticals Co., Ltd. Earnings and Revenue History

Income Statement >

SK Biopharmaceuticals Co., Ltd. Debt to Assets

Balance Sheet >

SK Biopharmaceuticals Co., Ltd. Cash Flow

Cash Flow >

SK Biopharmaceuticals Co., Ltd. Forecast EPS vs Actual EPS

Earnings >